美东时间周二，美国三大股指在震荡交投中收低，投资者在美联储公布利率决议前保持谨慎。 目前投资者普遍预计美联储将在周三(北京时间周四凌晨2点)宣布降息25个基点，以对冲美国劳动力市 场持续恶化的趋势，这一状况已在近期多项经济数据中有所体现。 市场关注的焦点在于，美联储对全年利率路径的预测，以及决策者们预计在2025年结束前究竟还会再降 息一次，还是两次。 周二稍早公布的数据显示，美国8月零售销售数据增幅高于预期，显示美国消费者支出依然强劲，但这 几乎没有改变市场对降息的预期。 市场动态 截至收盘，道指跌125.18点，跌幅为0.27%，报45758.27点；纳指跌14.79点，跌幅为0.07%，报22333.96 点；标普500指数跌8.49点，跌幅为0.13%，报6606.79点。 美股行业ETF中，公用事业ETF收跌1.82%，区域银行ETF跌1.04%，银行业ETF跌0.99%，科技行业 ETF、网络股指数ETF、全球科技股指数ETF至多跌0.35%，半导体ETF则收涨0.01%，可选消费ETF涨 0.61%，能源业ETF涨1.68%。 标普500指数11个板块中，医疗保健板块微涨0.03%，房地产板块跌 ...

投资者同时对其他消息反应平淡，包括美国参议院确认白宫经济顾问斯蒂芬·米兰出任美联储理事，以 及上诉法院驳回特朗普要求罢免美联储理事丽莎·库克的请求。 智通财经9月17日讯（编辑 牛占林）美东时间周二，美国三大股指在震荡交投中收低，投资者在美联储 公布利率决议前保持谨慎。 目前投资者普遍预计美联储将在周三(北京时间周四凌晨2点)宣布降息25个基点，以对冲美国劳动力市 场持续恶化的趋势，这一状况已在近期多项经济数据中有所体现。 市场关注的焦点在于，美联储对全年利率路径的预测，以及决策者们预计在2025年结束前究竟还会再降 息一次，还是两次。 周二稍早公布的数据显示，美国8月零售销售数据增幅高于预期，显示美国消费者支出依然强劲，但这 几乎没有改变市场对降息的预期。 Baird私人财富管理投资策略师Ross Mayfield表示："任何具有韧性的经济数据都只会强化联邦公开市场 委员会(FOMC)内部鹰派的立场……并可能让美联储主席鲍威尔在措辞上比市场所希望的更为鹰派。" 热门股表现 大型科技股涨跌不一，特斯拉收涨2.82%，Meta涨1.87%，亚马逊涨1.13%，苹果涨0.61%，谷歌A则收 跌0.18%，微软跌1 ...

Lange补充道："我们对这些数据感到兴奋，这是下一代胰淀素疗法首个3期临床数据，结果展现出前 景，我们期待在专门的3期RENEW项目中进一步验证Cagrilintide的潜力。" 周二，诺和诺德(NVO.US)涨逾2%，报57.12美元。消息面上，9月16日，诺和诺德表示，其新型减肥药 Cagrilintide在一项晚期临床试验中展现出良好结果。诺和诺德称，一项三期试验的早期分析显示，每周 一次的Cagrilintide单药注射在68周后帮助患者平均减重11.8%，而安慰剂组仅为2.3%。 诺和诺德首席科学官、研发执行副总裁Martin Holst Lange在声明中表示："在我们的临床试验中， Cagrilintide实现了显著减重，其机制不同于已批准的肥胖药物，并且耐受性良好。" Cagrilintide是一种新型减肥疗法，与现有的GLP-1类药物(如诺和诺德的司美格鲁肽和礼来的替尔泊肽) 不同，它是一种长效胰淀素类似物，通过模拟与胰岛素在胰腺中共同分泌的激素来增加饱腹感。 ...

Core Viewpoint - Novo Nordisk's new weight loss drug Cagrilintide shows promising results in late-stage clinical trials, leading to a stock price increase of over 2% to $57.12 [1] Group 1: Clinical Trial Results - Cagrilintide demonstrated an average weight loss of 11.8% after 68 weeks in a Phase 3 trial, compared to only 2.3% in the placebo group [1] - The drug is a long-acting insulin analog that increases satiety by mimicking hormones secreted alongside insulin in the pancreas, differing from existing GLP-1 medications [1] Group 2: Company Statements - Martin Holst Lange, Chief Scientific Officer and Executive Vice President of R&D at Novo Nordisk, expressed excitement over the significant weight loss achieved in clinical trials and noted the good tolerability of Cagrilintide [1] - The company anticipates further validation of Cagrilintide's potential in the dedicated Phase 3 RENEW project [1]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The Club's 10 things to watch Tuesday, Sept. 16 — Today's newsletter was written by Jeff Marks, the Club's director of portfolio analysis. 1. The S & P 500 and Nasdaq are set for a higher open this morning, aiming to extend yesterday's gains. Both indexes closed at record highs to kick off the week. Retail sales increased 0.6% month over month in August, the Census Bureau said, exceeding expectations of a 0.2% gain. It's the last key economic reading ahead of the Federal Reserve's interest rate decision tom ...

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.Novo Nordisk on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.Early analysis from a phase ...